Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cns Pharmaceuticals Inc (NQ: CNSP )

1.140 +0.090 (+8.57%)
Streaming Delayed Price Updated: 3:57 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 26,604
Open 1.050
Bid (Size) 1.030 (5)
Ask (Size) 1.590 (1)
Prev. Close 1.050
Today's Range 1.050 - 1.160
52wk Range 0.9903 - 13.43
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Lighting Up Malignant Tissues Could Boost Precision of Surgical Removal
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Hits Key Milestone in Global GBM Clinical Trial with the Enrollment of First Patient in Spain
Via Investor Brand Network

Performance

YTD
-57.14%
-57.14%
1 Month
-30.15%
-30.15%
3 Month
-47.95%
-47.95%
6 Month
-80.19%
-80.19%
1 Year
-88.91%
-88.91%

More News

Read More
Normalizing Blood Vessels in Tumors Could Improve Brain Cancer Immunotherapy
Via Investor Brand Network
Research Suggests Brain Cancers Could Be Detected Via Blood Tests
Via Investor Brand Network
Topics Death
Exposures Death
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces It Has No Exposure to Silicon Valley Bank Issues
Via Investor Brand Network
Study Finds Repeated Head Trauma Increases Brain Cancer Risk
Via Investor Brand Network
Researchers Find That Nutraceuticals May Be Useful in Preventing and Treating Cancer
Via Investor Brand Network
Topics Death
Exposures Death
Study Documents Dangers of Halting Opioid Treatments for Chronic Pain
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Potentially Pivotal Berubicin Trial
Via Investor Brand Network
Researchers Find Ways to Ease Cancer Treatment Outcome Prediction
Via Investor Brand Network
New AI Tool Helps Personalize Breast Cancer Therapy
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Why Titan International Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Research Finds Most Pediatric Oncologists Don’t Discuss Prognosis with Caregivers
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls First Patient in Spain in Key Global Trial Studying Berubicin for Treatment of GBM
Via Investor Brand Network
Study Finds Boosting White Blood Cell Counts May Improve Treatment Outcomes
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Pleased with Early Results from Global Clinical Trial
Via Investor Brand Network
Study Determines That How Proteins Move May Influence Brain Tumor Growth
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses ‘Lifeblood’ of Phase 2 Berubicin Trial
Via Investor Brand Network
Researchers Design a New Way to Kill Cancer Using Cancer Cells
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Be Evaluated in Investigator-Initiated Phase 1b/2 Trial
Via Investor Brand Network
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
Via ACCESSWIRE
TinyGemsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Poised to Potentially Change History
Via Investor Brand Network
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at Virtual Investor 2023 ‘Companies to Watch’
Via Investor Brand Network
Four Developments in Cancer Research That Occurred in 2022
Via Investor Brand Network
Topics Death
Exposures Death Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.